Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
1. 系统已在2025-12-11 16:14:20对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/s1470-2045(25)00543-1
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S1470204525005431
其他信息:
出版社: Elsevier BV
作者: Shukui Qin; Shanzhi Gu; Stephen L Chan; Yuxian Bai; Zhenggang Ren; Xiaoyan Lin; Zhendong Chen; Weidong Jia; Yongdong Jin; Yabing Guo; Xiaohua Hu; Zhiqiang Meng; Jun Liang; Jianping Xiong; Hong Ren; Fang Yang; Wei Li; Yajin Chen; Yong Zeng; Li Xu; Xianglin Yuan; Da Li; Alexander Sultanbaev; Monika Pazgan-Simon; Margaryta Pisetska; Davide Melisi; Dmitriy Ponomarenko; Jinghua Du; Wei Shi; Ann-Lii Cheng; Ahmed Kaseb; Arndt Vogel
